Clinical Trial Update: Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

View source ↗

Summary

Post-marketing surveillance study in Japan evaluating Calquence (acalabrutinib) as first-line therapy for previously untreated chronic lymphocytic leukemia, inc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: AstraZeneca | Conditions: Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma) | Status: COMPLETED